Oppenheimer analyst Jeff Jones raised the firm’s price target on Pharming (PHAR) to $41 from $40 and keeps an Outperform rating on the shares after the company announced Q2 results. Moving into the second half of 2025, Oppenheimer anticipates competitive pressure on Ruconest from Ekterly, potentially up to a 20% hit by year-end 2026 as patients try the oral option, its estimates counterbalanced by reduced expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
- Pharming Group Reports Strong Q2 2025 Revenue Growth
- Pharming Group Reports Strong Q2 2025 Financial Results and Business Update
- Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
- Pharming Group to Host Webcast on New APDS Study Findings